Harvey Richman, OD
Pediatrics · Manasquan, NJNPI 1336124445
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,596 of the $12,031 with a category attached, or 88.1%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Among pediatrics clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $39.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Alcon$1K
- Biotissue Holdings Inc.$992
- AbbVie$977
- Bausch & Lomb Americas Inc.$919
- Oyster Point Pharma, Inc.$678
- plus $5K from 24 others
What the payments were for
- Consulting fees$1,31511%
- Speaking & faculty fees$1001%
- Food & beverage$10,59688%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 54 | $2,725 |
| Alcon | 41 | $1,126 |
| Biotissue Holdings Inc. | 16 | $992 |
| AbbVie(2 entities) | 25 | $977 |
| Bausch & Lomb Americas Inc. | 31 | $919 |
| Oyster Point Pharma, Inc. | 22 | $678 |
| Sun Pharmaceutical Industries Inc. | 18 | $528 |
| Visioneering Technologies, Inc. | 5 | $436 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $412 |
| Coopervision Inc. | 16 | $370 |
| Amgen(2 entities) | 12 | $368 |
| Glaukos Corporation | 5 | $356 |
| AstraZeneca | 5 | $353 |
| Carl Zeiss Meditec, Inc. | 1 | $263 |
| Samsara Vision | 8 | $240 |
| Dompe US, Inc. | 6 | $200 |
| Novartis | 3 | $152 |
| Tarsus Pharmaceuticals, Inc. | 3 | $139 |
| LKC Technologies, Inc. | 3 | $128 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $111 |
| Maculogix, Inc. | 2 | $103 |
| Harrow Eye, LLC | 6 | $99 |
| Sanofi | 2 | $58 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| Johnson & Johnson | 1 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alcon Research LLC | 1 | $19 |
| Thea Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$981
- TYRVAYA$343
- CIRRUS HD-OCT$263
- CIRRUS 6000 with AngioPlex$263
- CLARUS$263
- ATLAS 500$263
- Prokera$253
- CEQUA$228
- INFUSE$228
- LUMIGAN$228
- RADIUS$144
- KXL System$141
- Photrexa$141
- Syfovre$125
- Rocklatan$125
- Rhopressa$125
- TEPEZZA$125
- LOTEMAX SM$125
- XIIDRA$125
- BEPREVE$123
How this compares
$12,031 in reported general payments places this provider in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $42,428 |
| LumiganBimatoprost | 59 | $24,805 |
| Cyclosporine | 15 | $14,903 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,783 |
| VyzultaLatanoprostene Bunod | 17 | $6,074 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,675 |
| Timolol Maleate | 25 | $922 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $555 |
| Latanoprost | 29 | $278 |
| ErythromycinErythromycin Base | 14 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $977 | $74,016108 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $919 | $6,07417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Other pediatrics in Manasquan
- Kelli BowerManasquan$3K
- Steven MateretskyHackensack$290K
- Sara RaymondMorristown$288K
- Andrew MulbergCamden$264K
- Bram GreenbergLakewood$200K
- David ApelianBoonton$149K
- Christopher AmatoGibbsboro$34K
- Syeda Amna HusainMarlboro$27K
- Nika DouvikasJersey City$27K
- Melanie DegliuominiHackensack$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.